Anne Li March 25th, 2017
Since 2000 — after years in which dexamethasone and melphalan was standard treatment — clinicians now have numerous options for patients with relapsed and/or refractory multiple myeloma (R/R MM). These include the immunomodulatory agent, thalidomide, as well as bortezomib, the first proteasome inhibitor introduced in 2004, and 8 other treatments: lenalidomide, pomalidomide, carfilzomib, ixazomib, vorinostat, panobinostat, elotuzumab, and daratumumab. Yet as the authors of a systematic literature review and network meta-analysis of treatment outcomes noted, “direct comparisons of these novel treatments…are lacking.”
See original article at: https://www.cancertherapyadvisor.com/multiple-myeloma/multiple-myeloma-meta-analysis-efficacy-current-treatments/article/644822/